Figure 2 suggests that GLP-1 RA therapy yields the most pronounced improvements in hepatic steatosis (Figure 2a) and fibrosis (Figure 2b), statistically significant compared to other drug classes. The gene discussed is GLP1R; the disease is Hepatic steatosis.